Loading
A phase 2 trial of Niraparib, Cetrelimab, Abiraterone acetate and Prednisone in prostate cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer is a phase 2 interventional study registered as NCT03431350 by Janssen Research & Development, LLC, with 136 participants enrolled, started 2018-03-02 and due to reach its primary completion in 2021-08-31. Interventions recorded: Niraparib 200 mg, Cetrelimab 240 mg, Cetrelimab 480 mg, Abiraterone acetate 1000 mg and Prednisone 5 mg. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
136 enrolled.
95% CI 9.9 to 43.7; Figures from the ClinicalTrials.gov results section (first posted 2023-11-18), not from a publication · 95% CI 0.5 to 36.4
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Combination 1: Part 2: Objective Response Rate (ORR)primary | Combination 1: Part 2 (Dose Expansion): Cohort 1A: BM+: Niraparib 200 mg + Cetrelimab 480 mg | 21 | 23.8% | - | - | link |
| Combination 1: Part 2 (Dose Expansion): Cohort 1B: BM-: Niraparib 200 mg + Cetrelimab 480 mg | 11 | 9.1% |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Niraparib, Abiraterone acetate, Prednisone, Johnson & Johnson and the tag pipeline.
Shares Abiraterone acetate, Prednisone, Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Abiraterone acetate, Prednisone, Johnson & Johnson, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Cetrelimab, Johnson & Johnson and the tag pipeline.
Shares Prednisone, Johnson & Johnson, Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Cetrelimab, Johnson & Johnson and the tag pipeline.
Shares Abiraterone acetate, Prednisone, Prostate cancer and the tag pipeline.
Shares Niraparib, PARP inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/